Rediff Logo
 Money
Line
Channels: Astrology | Broadband | Contests | E-cards | Money | Movies | Romance | Search | Wedding | Women
Partner Channels: Auto | Bill Pay | IT Education | Jobs | Lifestyle | Technology | Travel
Line
Home > Money > Reuters > Report
May 8, 2001 		Feedback  
  Money Matters

 -  Business Special
 -  Business Headlines
 -  Corporate Headlines
 -  Columns
 -  IPO Center
 -  Message Boards
 -  Mutual Funds
 -  Personal Finance
 -  Stocks
 -  Tutorials
 -  Search rediff

    
      

 
Reuters
 Search the Internet
         Tips
 Sites: Finance, Investment
E-Mail this report to a friend
Print this page

Wockhardt to market Eisai drug in India

Indian drugmaker Wockhardt Ltd said on Tuesday it will begin marketing in India one of Japan-based Eisai Company Ltd's top-selling drugs.

Wockhardt said in a statement it would begin selling Methycobal, Eisai's mecobalamine-based drug for the treatment of debilitating nerve disorders, such as those experienced by diabetic patients.

It said Methycobal was one of Eisai's top products, with annual sales of more than $400 million.

Wockhardt said it will begin selling the drug in July.

Wockhardt shares closed up 2.76 per cent at Rs 404.10, while the Sensex closed one per cent higher.

Back to top
(c) Copyright 2000 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Tell us what you think of this report